A long-acting GLP-1 receptor agonist, FDA-approved for type-2 diabetes and chronic weight management under brand names Ozempic, Wegovy, and Rybelsus. One of the most-studied incretin peptides.
Mechanism under study
Mimics the incretin hormone GLP-1: enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central pathways.
Research-reported dosing
Approved clinical regimens titrate slowly — e.g., 0.25 mg weekly up to 2.4 mg weekly for weight management — to manage gastrointestinal tolerability. Titration is central to its clinical use.
Supplied as solution or lyophilized research material; a 5 mg vial + 2 mL bacteriostatic water = 2500 mcg/mL.
A 250 mcg dose ≈ 10 units (25 mcg per unit).
Open this mix in the calculator →Dosing figures describe how this compound appears in the research literature and research-community references. They are not a recommendation for human use.
Semaglutide comparisons
Semaglutide FAQ
What is Semaglutide?
A long-acting GLP-1 receptor agonist, FDA-approved for type-2 diabetes and chronic weight management under brand names Ozempic, Wegovy, and Rybelsus. One of the most-studied incretin peptides.
What is the half-life of Semaglutide?
Approximately 7 days, enabling once-weekly clinical dosing.
What is the research-reported dosing for Semaglutide?
Approved clinical regimens titrate slowly — e.g., 0.25 mg weekly up to 2.4 mg weekly for weight management — to manage gastrointestinal tolerability. Titration is central to its clinical use.
How is Semaglutide reconstituted?
Supplied as solution or lyophilized research material; a 5 mg vial + 2 mL bacteriostatic water = 2500 mcg/mL.
Is Semaglutide FDA-approved?
Semaglutide has an approved status in at least one context — see the overview above for the specific brand, region, and indication. Research-grade material sold separately is for laboratory use only.
References
Guides featuring Semaglutide
Related peptides
Tirzepatide
Dual GIP / GLP-1 receptor agonist
A dual GIP and GLP-1 receptor agonist, FDA-approved as Mounjaro (type-2 diabetes) and Zepbound (weight management). Trials reported notably large reductions in body weight.
Retatrutide
Triple GIP / GLP-1 / glucagon receptor agonist
An investigational 'triple agonist' targeting the GIP, GLP-1, and glucagon receptors. Phase-2 trials reported among the largest weight reductions seen for an incretin agent. Not approved.
Tesamorelin
Stabilized GHRH analog
A stabilized GHRH analog that is FDA-approved (as Egrifta) to reduce excess visceral adipose tissue in HIV-associated lipodystrophy — one of the few peptides in this index with an approved human indication.